SCHEMBL4193023

SCHEMBL4193023

COc1ccc(N(Cc2cccnc2)c2cccc(OCCN3CCN(C)CC3)c2)cc1OC1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.48
PDE4D Q08499 4/20 0.48
PDE4B Q07343 2/20 0.48
PDE4C Q08493 2/20 0.48
QPCT Q16769 3/20 0.46
GRM2 Q14416 3/20 0.42
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
FGFR4 P22455 1/20 0.41
FGFR3 P22607 1/20 0.41
KDR P35968 1/20 0.41
ABCB1 P08183 1/20 0.40
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
LTA4H P09960 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158532 0.95 PDE4A (0.49) PDE4APDE4DPDE4BPDE4CQPCT
SCHEMBL4194667 0.90 PDE4A (0.49) PDE4APDE4DPDE4BPDE4CQPCT
SCHEMBL4206692 0.88 PDE4A (0.51) PDE4APDE4DPDE4BPDE4CQPCT
SCHEMBL1157824 0.87 PDE4A (0.52) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL4199907 0.87 PDE4A (0.47) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157687 0.87 PDE4A (0.58) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157584 0.86 PDE4A (0.52) PDE4APDE4DPDE4BPDE4CQPCT
SCHEMBL1157494 0.84 PDE4A (0.54) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL6952933 0.83 PDE4A (0.48) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157483 0.83 QPCT (0.54) PDE4APDE4DPDE4BPDE4CQPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.